Sacubitril/Valsartan Dosing for Heart Failure with Reduced Ejection Fraction

Initial Dosing Strategy

• The American College of Cardiology recommends starting sacubitril/valsartan at 49/51 mg twice daily for patients with high-dose ACE inhibitor or ARB exposure, and 24/26 mg twice daily for all other patients, including those with low/medium-dose ACE inhibitor or ARB, de novo initiation, and special populations with severe renal impairment, moderate hepatic impairment, or age ≥75 years 1, 2

Titration Schedule

• The target dose of 97/103 mg twice daily should be reached by doubling the dose every 2-4 weeks as tolerated, providing maximum mortality benefit, according to the American College of Cardiology 3, 4

Critical Transition Requirements

• A mandatory 36-hour washout period is required when switching from an ACE inhibitor to sacubitril/valsartan to avoid angioedema, as recommended by the American College of Cardiology 1

Managing Common Barriers to Optimal Dosing

Hypotension Management

• For patients with systolic blood pressure ≤100 mm Hg, ensure they are not volume-depleted before initiation, and consider reducing loop diuretic doses to mitigate hypotensive effects, as suggested by the American College of Cardiology 1, 4
• Asymptomatic hypotension does not require dose reduction, and patient education is essential, according to the American College of Cardiology and Praxis Medical Insights 4

Hospital Initiation Considerations

• In-hospital initiation after hemodynamic stabilization is feasible and should be pursued, with approximately 50% of patients achieving target dose within 10 weeks, as recommended by the American College of Cardiology 1, 2

Common Pitfalls to Avoid

• Failing to uptitrate due to asymptomatic hypotension or mild laboratory changes, which do not predict adverse outcomes, as noted by Praxis Medical Insights 4
• Permanent dose reductions should be avoided when temporary reductions with subsequent re-titration would be appropriate, according to Praxis Medical Insights 4